Inactive Instrument

Highlights ChemoCentryx, Inc.

Equities

CCXI

US16383L1061

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Amgen Completes ChemoCentryx Acquisition	22-10-20	MT
Amgen Inc. completed the acquisition of ChemoCentryx, Inc. from a group of shareholders.	22-10-19	CI
Swissmedic OKs ChemoCentryx's Combo Therapy For Rare Blood Vessel Disease	22-09-27	MT
UK Agency Recommends Tavneos Combo for Treatment of Rare Blood Vessel Disease	22-08-18	MT
Biotech stocks pin bounce back hopes on M&A boost	22-08-12	RE
ChemoCentryx, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-08	CI
Amgen Signals Additional $100 Million Hit to Revenue From Foreign Exchange Following Volume-Driven Second-Quarter Beat	22-08-05	MT
Amgen 2Q Profit Jumped After Write-Off From 2021 Acquisition	22-08-04	DJ
Amgen to Acquire Drugmaker ChemoCentryx in $3.7 Billion Deal	22-08-04	MT
ChemoCentryx Shares Soar Premarket on Amgen Takeover Deal	22-08-04	DJ
Amgen to Acquire ChemoCentryx in $3.7 Billion Deal	22-08-04	MT
Amgen to buy ChemoCentryx for $3.7 billion	22-08-04	RE
Chemocentryx Inc. Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered Pd-L1 Inhibitor, Ccx559, At the 2022 American Society of Clinical Oncology Annual Meeting	22-06-06	CI
ChemoCentryx Q1 Loss Widens as Revenue Declines	22-05-06	MT
Earnings Flash (CCXI) CHEMOCENTRYX Posts Q1 Revenue $5.46M	22-05-05	MT
ChemoCentryx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-05	CI
ChemoCentryx, Inc. Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, Ccx559, At American Association for Cancer Research Annual Meeting 2022	22-04-13	CI
ChemoCentryx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-01	CI
Earnings Flash (CCXI) CHEMOCENTRYX Reports Q4 Revenue $2.3M, vs. Street Est of $3.9M	22-03-01	MT
Earnings Flash (CCXI) CHEMOCENTRYX Reports Q4 Loss $-0.58, vs. Street Est of $-0.58	22-03-01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ChemoCentryx, Inc.

Equities

CCXI

US16383L1061

Highlights

Filters